1. The clinical utility of montelukast in paediatric respiratory diseases;Al-Saadi;Pak. J. Med. Sci.,2007
2. Al-Zamil, Hana A., Ai-Twaijiri, Ali S., Al-Mobeireek., Abdulla F., Mustafa, Ali A. 2005. Effects of zafirlukast on the function of human polymorphonuclear neutrophil leukocytes in asthmatic patients: a prospective, controlled, in vitro study. Curr. Ther. Res. 66(4), 279–293.
3. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism;Anderson;Br. J. Pharmacol.,2009
4. Anonymous. 2004. Drug Review. Asthma. Montelukast, drugs in context. Part E. Respir. Med. Infect. 1, 1–40.
5. Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury;Biber;Brain Inj.,2009